1 enrolling by invitation. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Enrolling by invitation 1 |
Follow Solid Tumors (Phase 1): new trials by email Literature Review of Solid Tumors (Phase 1) trials Research Report on Solid Tumors (Phase 1)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 RNDO-564, Pembrolizumab - Non Small Cell Lung Cancer, Cervical Cancer | Phase 1 | Enrolling by invitation | Rondo Therapeutics | 149 | 2025-11-17 | 2026-06-11 |
Adenocarcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Esophageal Squamous Cell Carcinoma (1) · Neoplasms (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1) · Urinary Bladder Neoplasms (1) · Uterine Cervical Neoplasms (1)
Breast Diseases (1) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Squamous Cell (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Esophageal Diseases (1) · Esophageal Neoplasms (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Genital Diseases (1)
pembrolizumab (1)
United States (1)